Recent advances in the prevention and treatment of skin cancer using photodynamic therapy

Expert Review of Anticancer Therapy

Volumn 10, Issue 11, 2010, Pages 1797-1809

  Zhao, Baozhong ^a   He, Yu Ying ^b  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

5 aminolevulinic acid; ALA; MAL; methyl 5 aminolevulinate; PDT; photodynamic therapy; photosensitizers; skin cancer; topical PDT

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; FLUOROURACIL; IMIQUIMOD; PHOTOFRIN; PHOTOSENSITIZING AGENT; PROGESTERONE; PROTOPORPHYRIN; REACTIVE OXYGEN METABOLITE; TEMOPORFIN; VERTEPORFIN;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; BOWENOID PAPULOSIS; CLINICAL TRIAL; FLUORESCENCE; HUMAN; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PHOTOTOXICITY; PRECANCER; REVIEW; SKIN CANCER; SQUAMOUS CELL CARCINOMA;

HUMANS; PHOTOCHEMOTHERAPY; SKIN NEOPLASMS;

EID: 78649314067     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.154     Document Type: Review

References (127)

1. Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat. Clin. Pract. Oncol. 4(8), 462-469 (2007).
2. Rogers HW, Weinstock MA, Harris AR et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch. Dermatol. 146(3), 283-287 (2010). • Most complete evaluation to date of the under-recognized epidemic of skin cancer in the USA.
3. Ackroyd R, Kelty C, Brown N, Reed M. The history of photodetection and photodynamic therapy. Photochem. Photobiol. 74(5), 656-669 (2001).
4. Daniell MD, Hill JS. A history of photodynamic therapy. Aust. NZ J. Surg. 61(5), 340-348 (1991).
5. Spikes JD. Primary Photoprocesses in Biology and Medicine. Berghausen RV, Jori G, Land EJ, Truscott TH (Eds). Plenum Press, NY, USA, 209-227 (1985).
6. Fitzpatrick TB, Pathak MA. Historical aspects of methoxsalen and other furocoumarins. J. Invest. Dermatol. 32(2), 229-231 (1959).
7. Moan J, Peng Q. An outline of the hundred-year history of PDT. Anticancer Res. 23 (5A), 3591-3600 (2003).
8. Pinthus JH, Bogaards A, Weersink R, Wilson BC, Trachtenberg J. Photodynamic therapy for urological malignancies: past to current approaches. J. Urol. 175(4), 1201-1207 (2006).
9. Juarranz A, Jaen P, Sanz-Rodriguez F, Cuevas J, Gonzalez S. Photodynamic therapy of cancer. Basic principles and applications. Clin. Transl. Oncol. 10(3), 148-154 (2008).
10. Jichlinski P. Photodynamic applications in superfcial bladder cancer: facts and hopes! J. Environ. Pathol. Toxicol. Oncol. 25 (1-2), 441-451 (2006).
11. Wiedmann MW, Caca K. General principles of photodynamic therapy (PDT) and gastrointestinal applications. Curr. Pharm. Biotechnol. 5(4), 397-408 (2004).
12. Barr H, Dix AJ, Kendall C, Stone N. Review article: the potential role for photodynamic therapy in the management of upper gastrointestinal disease. Aliment. Pharmacol. Ther. 15(3), 311-321 (2001).
13. Ost D. Photodynamic therapy in lung cancer. A review. Methods Mol. Med. 75, 507-526 (2003).
14. Sutedja TG, Postmus PE. Photodynamic therapy in lung cancer. A review. J. Photochem. Photobiol. B Biol. 36(2), 199-204 (1996).
15. Photodynamic therapy with verteporfn for age-related macular degeneration. American Academy of Ophthalmology. Ophthalmology 107(12), 2314-2317 (2000).
16. Mittra RA, Singerman LJ. Recent advances in the management of age-related macular degeneration. Optom. Vis. Sci. 79(4), 218-224 (2002).
17. Blume JE, Oseroff AR. Aminolevulinic acid photodynamic therapy for skin cancers. Dermatol. Clin. 25(1), 5-14 (2007). • Comprehensive review on 5-aminolevulinic acid photodynamic therapy (PDT) in the treatment and prevention of skin cancer.
18. Dougherty TJ. A brief history of clinical photodynamic therapy development at Roswell Park Cancer Institute. J. Clin. Laser Med. Surg 14(5), 219-221 (1996).
19. Zeitouni NC, Oseroff AR, Shieh S. Photodynamic therapy for nonmelanoma skin cancers. Current review and update. Mol. Immunol. 39 (17-18), 1133-1136 (2003).
20. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J. Photochem. Photobiol. B Biol. 6 (1-2), 143-148 (1990).
21. Moan J. On the diffusion length of singlet oxygen in cells and tissues. J. Photochem. Photobiol. B Biol. 6(3), 343-347 (1990).
22. Foote CS. Definition of type I and type II photosensitized oxidation. Photochem. Photobiol. 54(5), 659(1991).
23. Garcia-Zuazaga J, Cooper KD, Baron ED. Photodynamic therapy in dermatology: current concepts in the treatment of skin cancer. Expert Rev. Anticancer Ther. 5(5), 791-800 (2005). • • Comprehensive review on current concepts in PDT treatment of skin cancer.
24. Kormeili T, Yamauchi PS, Lowe NJ. Topical photodynamic therapy in clinical dermatology. Br. J. Dermatol. 150(6), 1061-1069 (2004).
25. Ceburkov O, Gollnick H. Photodynamic therapy in dermatology. Eur. J. Dermatol. 10(7), 568-575 (2000).
26. Cappugi P, Campolmi P, Mavilia L, Prignano F, Rossi R. Topical 5-aminolevulinic acid and photodynamic therapy in dermatology: a minireview. J. Chemother. 13(5), 494-502 (2001).
27. Brancaleon L, Moseley H. Laser and non-laser light sources for photodynamic therapy. Lasers Med. Sci. 17(3), 173-186 (2002).
28. Palumbo G. Photodynamic therapy and cancer: a brief sightseeing tour. Expert Opin. Drug. Deliv. 4(2), 131-148 (2007).
29. Evans J. High-tech bandages lighten the load of light therapy. Nat. Med. 15(7), 713(2009). • A breakthrough in organic light-emitting diode light devices for PDT treatment of skin cancer.
30. Zhu TC, Finlay JC, Hahn SM. Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafn lutetiummediated photodynamic therapy. J. Photochem. Photobiol. B Biol. 79(3), 231-241 (2005).
31. Panjehpour M, Overholt BF, Phan MN, Haydek JM. Optimization of light dosimetry for photodynamic therapy of Barrett's esophagus: efficacy vs. incidence of stricture after treatment. Gastrointest. Endosc. 61(1), 13-18 (2005).
32. Dragieva G, Scharer L, Dummer R, Kempf W. Photodynamic therapy - a new treatment option for epithelial malignancies of the skin. Onkologie 27(4), 407-411 (2004).
33. Fritsch C, Goerz G, Ruzicka T. Photodynamic therapy in dermatology. Arch. Dermatol. 134(2), 207-214 (1998).
34. Moan J, Berg K. Photo chemotherapy of cancer: experimental research. Photochem. Photobiol. 55(6), 931-948 (1992).
35. Young SW, Woodburn KW, Wright M et al. Lutetium texaphyrin (PCI-0123): a near-infrared, water-soluble photosensitizer. Photochem. Photobiol. 63(6), 892-897 (1996).
36. Woodburn KW, Fan Q, Kessel D, Luo Y, Young SW. Photodynamic therapy of B16F10 murine melanoma with lutetium texaphyrin. J. Invest. Dermatol. 110(5), 746-751 (1998).
37. Josefsen LB, Boyle RW. Photodynamic therapy: novel thirdgeneration photosensitizers one step closer? Br. J. Pharmacol. 154(1), 1-3 (2008).
38. Babilas P, Karrer S, Sidoroff A, Landthaler M, Szeimies RM. Photodynamic therapy in dermatology - an update. Photodermatol Photoimmunol. Photomed. 21(3), 142-149 (2005).
39. Morton CA. Methyl aminolevulinate (Metvix) photodynamic therapy - practical pearls. J. Dermatolog. Treat. 14 (Suppl. 3), 23-26 (2003).
40. Morton CA, Brown SB, Collins S et al Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br. J. Dermatol. 146(4), 552-567 (2002).
41. Morton CA. Photodynamic therapy for nonmelanoma skin cancer - and more? Arch. Dermatol. 140(1), 116-120 (2004).
42. Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. Br. J. Dermatol. 159(6), 1245-1266 (2008). • • Systematic guidelines and updates for topical PDT.
43. Basset-Seguin N, Ibbotson SH, Emtestam L et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superfcial basal cell carcinoma: a 5 year randomized trial. Eur. J. Dermatol. 18(5), 547-553 (2008).
44. Lehmann P. Methyl aminolaevulinatephotodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. Br. J. Dermatol. 156(5), 793-801 (2007).
45. Procianoy F, Cruz AA, Baccega A, Ferraz V, Chahud F. Aggravation of eyelid and conjunctival malignancies following photodynamic therapy in DeSanctis-Cacchione syndrome. Ophthal Plast. Reconstr. Surg 22(6), 498-499 (2006).
46. Holmes MV, Dawe RS, Ferguson J, Ibbotson SH. A randomized, doubleblind, placebo-controlled study of the efficacy of tetracaine gel (Ametop) for pain relief during topical photodynamic therapy. Br. J. Dermatol. 150(2), 337-340 (2004).
47. Langan SM, Collins P. Randomized, double-blind, placebo-controlled prospective study of the efficacy of topical anaesthesia with a eutetic mixture of lignocaine 2.5% and prilocaine 2.5% for topical 5-aminolaevulinic acidphotodynamic therapy for extensive scalp actinic keratoses. Br. J. Dermatol. 154(1), 146-149 (2006).
48. Pagliaro J, Elliott T, Bulsara M, King C, Vinciullo C. Cold air analgesia in photodynamic therapy of basal cell carcinomas and Bowens disease: an effective addition to treatment: a pilot study. Dermatol. Surg 30(1), 63-66 (2004).
49. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1(8589), 795-797 (1988).
50. Szeimies RM, Karrer S, Sauerwald A, Landthaler M. Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology (Basel) 192(3), 246-251 (1996).
51. Jeffes EW, McCullough JL, Weinstein GD et al. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Arch. Dermatol. 133(6), 727-732 (1997).
52. Piacquadio DJ, Chen DM, Farber HF et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigatorblinded, Phase 3, multicenter trials. Arch. Dermatol. 140(1), 41-46 (2004).
53. Kaufmann R, Spelman L, Weightman W et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinatephotodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br. J. Dermatol. 158(5), 994-999 (2008).
54. Wiegell SR, Haedersdal M, Eriksen P, Wulf HC. Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolaevulinate and home-based daylight exposure: a double-blinded randomized clinical trial. Br. J. Dermatol. 160(6), 1308-1314 (2009).
55. Hauschild A, Popp G, Stockfeth E et al. Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch. Exp. Dermatol. 18(2), 116-121 (2009).
56. Moloney FJ, Collins P. Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br. J. Dermatol. 157(1), 87-91 (2007).
57. Morton C, Campbell S, Gupta G et al. Intraindividual, right-left comparison of topical methyl aminolaevulinatephotodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br. J. Dermatol. 155(5), 1029-1036 (2006).
58. Szeimies RM. Methyl aminolevulinatephotodynamic therapy for basal cell carcinoma. Dermatol. Clin. 25(1), 89-94 (2007).
59. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int. J. Dermatol. 45(5), 489-498 (2006).
60. Peng Q, Warloe T, Berg K et al. 5-aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 79(12), 2282-2308 (1997).
61. Thissen MR, Schroeter CA, Neumann HA. Photodynamic therapy with d-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br. J. Dermatol. 142(2), 338-339 (2000).
62. Wang I, Bendsoe N, Klinteberg CA et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a Phase III clinical trial. Br. J. Dermatol. 144(4), 832-840 (2001).
63. Soler AM, Warloe T, Berner A, Giercksky KE. A follow-up study of recurrence and cosmesis in completely responding superfcial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br. J. Dermatol. 145(3), 467-471 (2001).
64. Vinciullo C, Elliott T, Francis D et al. Photodynamic therapy with topical methyl aminolaevulinate for 'diffcult-to-treat' basal cell carcinoma. Br. J. Dermatol. 152(4), 765-772 (2005).
65. Horn M, Wolf P, Wulf HC et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br. J. Dermatol. 149(6), 1242-1249 (2003).
66. Rhodes LE, de Rie MA, Leifsdottir R et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch. Dermatol. 143(9), 1131-1136 (2007).
67. Moseley H, Allen JW, Ibbotson S et al. Ambulatory photodynamic therapy: a new concept in delivering photodynamic therapy. Br. J. Dermatol. 154(4), 747-750 (2006).
68. de Haas ER, Sterenborg HJ, Neumann HA, Robinson DJ. Response of Bowen disease to ALA-PDT using a single and a 2-fold illumination scheme. Arch. Dermatol. 143(2), 264-265 (2007).
69. Morton C, Horn M, Leman J et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch. Dermatol. 142(6), 729-735 (2006).
70. Brookes P T, Jhawar S, Hinton CP, Murdoch S, Usman T. Bowen's disease of the nipple - a new method of treatment. Breast 14(1), 65-67 (2005).
71. Tan B, Sinclair R, Foley P. Photodynamic therapy for subungual Bowen's disease. Australas. J. Dermatol. 45(3), 172-174 (2004).
72. Usmani N, Stables GI, Telfer NR, Stringer MR. Subungual Bowen's disease treated by topical aminolevulinic acid-photodynamic therapy. J. Am. Acad. Dermatol. 53 (5 Suppl. 1), S273-S276 (2005).
73. Ball SB, Dawber R P. Treatment of cutaneous Bowen's disease with particular emphasis on the problem of lower leg lesions. Australas. J. Dermatol. 39(2), 63-68 (1998).
74. Guillen C, Sanmartin O, Escudero A, Botella-Estrada R, Sevila A, Castejon P. Photodynamic therapy for in situ squamous cell carcinoma on chronic radiation dermatitis after photosensitization with 5-aminolaevulinic acid. J. Eur. Acad. Dermatol. Venereol. 14(4), 298-300 (2000).
75. Souza CS, Felicio LB, Bentley MV et al. Topical photodynamic therapy for Bowen's disease of the digit in epidermolysis bullosa. Br. J. Dermatol. 153(3), 672-674 (2005).
76. Stables GI, Stringer MR, Robinson DJ, Ash DV. Erythroplasia of Queyrat treated by topical aminolaevulinic acid photodynamic therapy. Br. J. Dermatol. 140(3), 514-517 (1999).
77. Varma S, Holt PJ, Anstey AV. Erythroplasia of queyrat treated by topical aminolaevulinic acid photodynamic therapy: a cautionary tale. Br. J. Dermatol. 142(4), 825-826 (2000).
78. Wieland U, Jurk S, Weissenborn S, Krieg T, Pfster H, Ritzkowsky A. Erythroplasia of Queyrat: coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ. J. Invest. Dermatol. 115(3), 396-401 (2000).
79. Lee MR, Ryman W. Erythroplasia of Queyrat treated with topical methyl aminolevulinate photodynamic therapy. Australas. J. Dermatol. 46(3), 196-198 (2005).
80. Paoli J, Ternesten Bratel A, Lowhagen GB, Stenquist B, Forslund O, Wennberg AM. Penile intraepithelial neoplasia: results of photodynamic therapy. Acta Derm. Venereol. 86(5), 418-421 (2006).
81. Coors EA, von den Driesch P. Topical photodynamic therapy for patients with therapy-resistant lesions of cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 50(3), 363-367 (2004).
82. Leman JA, Dick DC, Morton CA. Topical 5-ALA photodynamic therapy for the treatment of cutaneous T-cell lymphoma. Clin. Exp. Dermatol. 27(6), 516-518 (2002).
83. Zane C, Venturini M, Sala R, Calzavara-Pinton P. Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma. Photodermatol. Photoimmunol. Photomed. 22(5), 254-258 (2006).
84. Mori M, Campolmi P, Mavilia L, Rossi R, Cappugi P, Pimpinelli N. Topical photodynamic therapy for primary cutaneous B-cell lymphoma: a pilot study. J. Am. Acad. Dermatol. 54(3), 524-526 (2006).
85. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N. Engl. J. Med. 348(17), 1681-1691 (2003).
86. Dragieva G, Hafner J, Dummer R et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 77(1), 115-121 (2004).
87. Dragieva G, Prinz BM, Hafner J
88. et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br. J. Dermatol. 151(1), 196-200 (2004).
89. Schleier P, Hyckel P, Berndt A et al. Photodynamic therapy of virusassociated epithelial tumours of the face in organ transplant recipients. J. Cancer Res. Clin. Oncol. 130(5), 279-284 (2004).
90. Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm. Venereol. 86(1), 25-28 (2006).
91. de Graaf YG, Kennedy C, Wolterbeek R, Collen AF, Willemze R, Bouwes Bavinck JN. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J. Invest. Dermatol. 126(3), 569-574 (2006).
92. Perrett CM, McGregor JM, Warwick J et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br. J. Dermatol. 156(2), 320-328 (2007).
93. Zheng W, Olivo M, Soo KC. The use of digitized endoscopic imaging of 5-ALA-induced PpIX fluorescence to detect and diagnose oral premalignant and malignant lesions in vivo. Int. J. Cancer 110(2), 295-300 (2004).
94. Kriegmair M, Baumgartner R, Knuchel R, Stepp H, Hofstadter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J. Urol. 155(1), 105-109 (1996).
95. Hillemanns P, Weingandt H, Baumgartner R, Diebold J, Xiang W, Stepp H. Photodetection of cervical intraepithelial neoplasia using 5-aminolevulinic acid-induced porphyrin fluorescence. Cancer 88(10), 2275-2282 (2000).
96. Baumgartner R, Huber RM, Schulz H et al. Inhalation of 5-aminolevulinic acid: a new technique for fluorescence detection of early stage lung cancer. J. Photochem. Photobiol. B Biol. 36(2), 169-174 (1996).
97. Fritsch C, Becker-Wegerich PM, Menke H, Ruzicka T, Goerz G, Olbrisch RR. Successful surgery of multiple recurrent basal cell carcinomas guided by photodynamic diagnosis. Aesthetic Plast. Surg. 21(6), 437-439 (1997).
98. Calzavara-Pinton PG, Venturini M, Sala R. Photodynamic therapy: update 2006. Part 2: clinical results. J. Eur. Acad. Dermatol. Venereol. 21(4), 439-451 (2007).
99. Ericson MB, Sandberg C, Gudmundson F, Rosen A, Larko O, Wennberg AM. Fluorescence contrast and threshold limit: implications for photodynamic diagnosis of basal cell carcinoma. J. Photochem. Photobiol. B Biol. 69(2), 121-127 (2003).
100. Wennberg AM, Gudmundson F, Stenquist B et al. In vivo detection of basal cell carcinoma using imaging spectroscopy. Acta Derm. Venereol. 79(1), 54-61 (1999).
101. Martin A, Tope WD, Grevelink JM et al. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Arch. Dermatol. Res. 287(7), 665-674 (1995).
102. Peng Q, Soler AM, Warloe T, Nesland JM, Giercksky KE. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J. Photochem. Photobiol. B Biol. 62(3), 140-145 (2001).
103. Stender IM, Bech-Thomsen N, Poulsen T, Wulf HC. Photodynamic therapy with topical d-aminolevulinic acid delays UV photocarcinogenesis in hairless mice. Photochem. Photobiol. 66(4), 493-496 (1997).
104. Sharfaei S, Viau G, Lui H, Bouffard D, Bissonnette R. Systemic photodynamic therapy with aminolaevulinic acid delays the appearance of ultraviolet-induced skin tumours in mice. Br. J. Dermatol. 144(6), 1207-1214 (2001).
105. Bissonnette R. Chemopreventative thoughts for photodynamic therapy. Dermatol. Clin. 25(1), 95-100 (2007).
106. Oseroff A. PDT as a cytotoxic agent and biological response modifer: implications for cancer prevention and treatment in immunosuppressed and immunocompetent patients. J. Invest. Dermatol. 126(3), 542-544 (2006).
107. Gollnick SO, Brackett CM. Enhancement of anti-tumor immunity by photodynamic therapy. Immunol. Res. 46 (1-3), 216-226 (2010). • Comprehensive review on the ability of PDT to enhance anti-tumor immunity.
108. Pervaiz S, Olivo M. Art and science of photodynamic therapy. Clin. Exp. Pharmacol. Physiol. 33 (5-6), 551-556 (2006).
109. Zhou Q, Olivo M, Lye KY, Moore S, Sharma A, Chowbay B. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. Cancer Chemother. Pharmacol. 56(6), 569-577 (2005).
110. Ferrario A, Von Tiehl K, Wong S, Luna M, Gomer CJ. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res. 62(14), 3956-3961 (2002).
111. Akita Y, Kozaki K, Nakagawa A et al Cyclo oxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity. Br. J. Dermatol 151(2), 472-480 (2004).
112. Wang XL, Wang HW, Guo MX, Xu SZ. Treatment of skin cancer and pre-cancer using topical ALA-PDT - a single hospital experience. Photodiagnosis Photodyn. Ther. 5(2), 127-133 (2008).
113. Wang XL, Wang HW, Guo MX, Huang Z. Combination of immunotherapy and photodynamic therapy in the treatment of Bowenoid papulosis. Photodiagnosis Photodyn. Ther. 4(2), 88-93 (2007).
114. Cormode DP, Skajaa T, Fayad ZA, Mulder WJ. Nanotechnology in medical imaging: probe design and applications. Arterioscler. Thromb. Vasc. Biol. 29(7), 992-1000 (2009).
115. Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv. Drug Deliv. Rev. 60(15), 1627-1637 (2008).
116. de Leeuw J, de Vijlder HC, Bjerring P, Neumann HA. Liposomes in dermatology today. J. Eur. Acad. Dermatol. Venereol. 23(5), 505-516 (2009).
117. Konan YN, Gurny R, Allemann E. State of the art in the delivery of photosensitizers for photodynamic therapy. J. Photochem. Photobiol. B Biol. 66(2), 89-106 (2002).
118. Gomes AJ, Lunardi CN, Tedesco AC. Characterization of biodegradable poly (d, llactide-co-glycolide) nanoparticles loaded with bacteriochlorophyll-a for photodynamic therapy. Photomed. Laser Surg. 25(5), 428-435 (2007).
119. Jang WD, Nishiyama N, Zhang GD et al. Supramolecular nanocarrier of anionic dendrimer porphyrins with cationic block copolymers modifed with polyethylene glycol to enhance intracellular photodynamic efficacy. Angew. Chem. Int. Ed. Engl. 44(3), 419-423 (2005).
120. Cheng Y, Samia AC, Meyers JD, Panagopoulos I, Fei B, Burda C. Highly effcient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J. Am. Chem. Soc. 130(32), 10643-10647 (2008).
121. Brevet D, Gary-Bobo M, Raehm L et al. Mannose-targeted mesoporous silica nanoparticles for photodynamic therapy. Chem. Commun. (12), 1475-1477 (2009).
122. Tu HL, Lin YS, Lin HY et al. In vitro studies of functionalized mesoporous silica nanoparticles for photodynamic therapy. Adv. Mater. 21(2), 172-177 (2009).
123. Cheng SH, Lee CH, Yang CS, Tseng FG, Mou CY, Lo LW. Mesoporous silica nanoparticles functionalized with an oxygen-sensing probe for cell photodynamic therapy: potential cancer theranostics. J. Mater. Chem. 19(9), 1252-1257 (2009).
124. Roy I, Ohulchanskyy TY, Pudavar HE et al. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J. Am. Chem. Soc. 125(26), 7860-7865 (2003). • • Preparation of a novel silica na nop article-delivery system for PDT.
125. Bechet D, Couleaud P, Frochot C, Viriot ML, Guillemin F, Barberi-Heyob M. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol. 26(11), 612-621 (2008).
126. Kuphal S, Bosserhoff A. Recent progress in understanding the pathology of malignant melanoma. J. Pathol. 219(4), 400-409 (2009).
127. Zhao B, Yin JJ, Bilski PJ, Chignell CF, Roberts JE, He YY. Enhanced photodynamic efficacy towards melanoma cells by encapsulation of Pc4 in silica nanoparticles. Toxicol. Appl. Pharmacol. 241(2), 163-172 (2009).